Table 3.
Drug susceptibility test data of the MTBC clinical isolates
| Details | Number of Isolates | Percentage (%) |
|---|---|---|
| No. of Isolates DST Done | 193 | |
| Total No. of Sensitive Isolates | 138 | 71.5 |
| Total No. of Resistant Isolates | 55 | 28.5 |
| Drug Resistance Type | ||
| Pyrazinamide | 33 | 17 |
| Isoniazid | 7 | 3.6 |
| Rifampicin | 2 | 1.0 |
| EMB | 0 | 0.0 |
| Isoniazid and Rifampicin (MDR) | 3 | 1.6 |
| Polyresistant Hr-TB | 6 | 3.1 |
| Polyresistant RR-TB | 0 | 0.0 |
| MDR- and EMB-Resistant Isolates | 2 | 1.03 |
| No. of Isolates Resistant to All Firstline Anti-TB Drugs | 2 | 1.03 |
DST = drug susceptibility test; EMB = ethambutol; MDR = multidrug resistance; MTBC = Mycobacterium tuberculosis complex; polyresistant Hr-TB = resistant to INH, PZA, and/or EMB but sensitive to RIF; polyresistant RR-TB = resistant to RIF, PZA, and/or EMB but sensitive to INH.